Bionas cell profiling device selected by Solvay Pharmaceuticals for Target Validation
"It is known that angiotensin 1-8 (angiotensin II) acts via two receptors. The AT1 receptor mediates vasoconstriction upon stimulation, whereas the AT2 receptor is implicated in hypotensive effects. However, the mechanism through which angiotensin 1-7 induces its powerful hypotensive effect were unclear," explains Dr. Eric Ronken, Principal Scientist at Solvay.
On-line monitoring of endothelial cell physiology and its changes upon challenges by angiotensin 1-7 helped in delineating the mechanism of action by this peptide. "The Bionas system allows us to extend and optimize target validation studies by bringing the targets back into their physiological context", says Dr. Eric Ronken.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.